Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568822 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA | |
| SCHEMBL11375460 | 0.78 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2KDM4ELMNAKMT2A | |
| SCHEMBL15966805 | 0.77 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2KDM4EMAPTGAA | |
| SCHEMBL20568495 | 0.75 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KDM4EMAPTGAA | |
| SCHEMBL26437234 | 0.75 | LMNA (0.54) | ALDH1A1SMN1; SMN2MAPTGAALMNA | |
| SCHEMBL2579591 | 0.73 | KDM4E (0.48) | ALDH1A1SMN1; SMN2KDM4EMAPTGAA | |
| SCHEMBL26437235 | 0.73 | NR1H2 (0.56) | ALDH1A1SMN1; SMN2KDM4EMAPTGAA | |
| SCHEMBL17633720 | 0.72 | KDM4E (0.60) | ALDH1A1SMN1; SMN2KDM4EGAAL3MBTL1 | |
| SCHEMBL11383580 | 0.71 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KDM4EMAPTLMNA | |
| SCHEMBL15328300 | 0.71 | CYP3A4 (0.53) | ALDH1A1SMN1; SMN2MAPTGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3630749-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215798-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 3048/4885SMN1; SMN2 4338/4885KDM4E 495/4885 |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | ALDH1A1 3048/4885SMN1; SMN2 4338/4885KDM4E 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.